Position:Axxelis Expert Group
For the past eight years, as head of Life Cycle Strategy at Novartis (General Medicine), Marc focused on supporting the teams, starting from phase II to end of Life Cycle, to identify, assess and value the incremental developments. Marc operated as a center of excellence for Life Cycle Strategy and on an internal consultancy mode. Marc also focused on select early developments with Intellectual Property or commercial challenges, to propose alternative viable development path and obtaining management approval for full development. Previous Global Brand Strategy and Development Experience Worldwide Brand Director for Voltaren, Novartis. Tiger Team Leader for the CVM BF & Diovan defense at LoE: to maximize commercial value of Diovan through an integrated approach to protect exclusivity rights. Enforced Exforge Data Exclusivity in Europe (till 2017/2018). International Project Team Leader for Certican®, Novartis. Under tenure, Certican® approved in Japan and FDA submitted in the US. Director New Product, Marketing, Oporia® Global Development Team, at Pfizer, N.Y., USA. BD&L and partnering Experiences At Novartis, Marc supported the Alliance Management with Sandoz, to develop the transition and launch plans of the Novartis Pharma product going generic (RxGx planning). He also acted at Alliance Manager for development and commercial partners for the pain franchise and managed the alliance with a key BD&L partner (Abbott Vascular for Xience V, an everolimus coated stent). Director Corporate Development & Licensing, at Warner Lambert HQ, USA. Ethypharm France, as Area Manager for Central/Eastern Europe and Scandinavia. In this licensing-out role, marc developed the business via BD&L Agreements, completing 20 out-licensing and development agreements.